Research Article: Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

Date Published: June 20, 2018

Publisher: BioMed Central

Author(s): Isabelle Bos, Frans R. Verhey, Inez H. G. B. Ramakers, Heidi I. L. Jacobs, Hilkka Soininen, Yvonne Freund-Levi, Harald Hampel, Magda Tsolaki, Åsa K. Wallin, Mark A. van Buchem, Ania Oleksik, Marcel M. Verbeek, Marcel Olde Rikkert, Wiesje M. van der Flier, Philip Scheltens, Pauline Aalten, Pieter Jelle Visser, Stephanie J. B. Vos.

http://doi.org/10.1186/s13195-018-0391-x

Abstract

Partial Text

Upon publication of this article [1], it was noticed that there were some inconsistencies in Tables 1, 2 and 3. Some of the superscript letters were incorrectly assigned. Please see below the correct tables:Table 1Comparisons of baseline and follow-up characteristics by Aβ and WMH statusAβ- WMH-Aβ- WMH+Aβ + WMH-Aβ + WMH+n = 140n = 39n = 63n = 29Baseline characteristics Age61.7 (8.3)B,C,D71.3 (7.7)A,C66.7 (7.8)A,B,D74.1 (5.0)A,C Female, n94 (67)C23 (59)32 (51)A16 (55) Education in years10.9 (3.1)11.9 (3.3)11.1 (3.1)10.3 (2.9) Hypertension, n*43 (34)9 (25)15 (25)9 (32) Obesity, n*15 (14)3 (11)4 (8)4 (21) Diabetes, n*16 (21)3 (15)3 (7)5 (28) APOE-ε4 carrier, n*33 (51)B5 (24)A,C,D29 (62)B10 (56)B Diagnosis MCI, n70 (50)D21 (54)D40 (64)22 (76)A,B  amnestic MCI (% within MCI group)40 (57)15 (71)27 (68)17 (77)  non-amnestic MCI (% within MCI group)30 (43)6 (29)13 (33)5 (23) CSF Aβ 1–42, pg/ml973.6 (312.0)C,D885.0 (242.0)C,D404.3 (102.6)A,B419.3 (97.2)A,B White matter hyperintensities†0.7 (0.5)B,D2.3 (0.4)A,C0.8 (0.4)B,D2.4 (0.5)A,CFollow-up characteristics Follow-up time2.1 (1.5)2.2 (1.3)2.1 (1.2)2.4 (1.2) Time to progression to dementia1.3 (0.5)B2.0 (0.7)A1.7 (0.7)2.1 (1.2) Progression to dementia, n8 (6)B,C,D9 (23)A18 (29)A11 (38)A – AD-type dementia, n2 (1)B,C,D7 (18)A18 (29)A10 (35)A – Vascular dementia, n0 (0)2 (5)0 (0)1 (3) – Frontotemporal dementia, n4 (3)0 (0)0 (0)0 (0) – Lewy Body dementia, n1 (1)0 (0)0 (0)0 (0) – Dementia with unknown etiology, n1 (1)0 (0)0 (0)0 (0)Results are mean (SD) for continuous variables or frequency (%). Hypertension, obesity, diabetes and APOE ε4 genotype were only available in a subgroup of the sampleAbbreviations: Aβ amyloid-beta, AD Alzheimer’s disease, APOE Apolipoprotein E, MCI mild cognitive impairment†WMH measured by the Fazekas scale, range 0–3Ap < 0.05 compared to Aβ- WMH-Bp < 0.05 compared to Aβ- WMH+Cp < 0.05 compared to Aβ + WMH-Dp < 0.05 compared to Aβ + WMH+Table 2Values of neurodegenerative markers by Aβ/WMH groupsAβ- WMH-Aβ- WMH+Aβ + WMH-Aβ + WMH+Neurodegeneration markersn = 140n = 39n = 63n = 29MTA score1.2 (1.2)B,C,D2.6 (1.6)A,D2.1 (1.6)A,D3.4 (1.8)A,B,C MTA abnormal, n62 (45)B,C,D32 (82)A41 (67)A,D26 (93)A,CP-tau, pg/ml54.5 (27.7)C63.2 (29.3)77.0 (56.3)A65.2 (38.2) P-tau abnormal, n53 (38)C22 (58)45 (71)A15 (52)T-tau, pg/ml314.7 (202.0)B,C,D438.4 (248.0)A499.3 (413.8)A426.2 (275.2)A T-tau abnormal, n36 (26)B,C,D20 (53)A36 (57)A14 (48)AResults are mean (SD) and number (%). All analyses were adjusted for study, baseline diagnosis and demographicsAbbreviations: Aβ amyloid-beta, MTA medial temporal lobe atrophy, P-tau phosphorylated tau, T-tau Total tau, WMH white matter hyperintensitiesAp < 0.05 compared to Aβ- WMH-Bp < 0.05 compared to Aβ- WMH+.Cp < 0.05 compared to Aβ + WMH-.Dp < 0.05 compared to Aβ + WMH+.Table 3Cognitive performance and decline by Aβ/WMH groupsAβ- WMH-Aβ- WMH+Aβ + WMH-Aβ + WMH+MMSE*n140396227Baseline27.79 (27.39, 28.19)27.52 (26.83, 28.21)27.20 (26.62, 27.78)27.40 (26.54, 28.25)Slope−0.01 (− 0.15, 0.12)− 0.29 (− 0.55, − 0.02)−0.22 (− 0.44, − 0.01)− 0.31 (− 0.62, 0.00)Memory delayed recall z-scoren133375827Baseline−0.48 (− 0.72, − 0.24)B,C,D−1.04 (− 1.48, − 0.61)A−1.04 (− 1.41, − 0.68)A−1.33 (− 1.86, − 0.80)ASlope0.05 (− 0.03, 0.13)0.02 (− 0.12, 0.17)0.02 (− 0.11, 0.14)−0.07 (− 0.24, 0.09)Executive functioning z-scoren130376024Baseline−0.48 (− 0.76, − 0.21)−0.41 (− 0.92, 0.09)−0.78 (− 1.18, − 0.37)−1.12 (− 1.73, − 0.50)Slope0.06 (− 0.02, 0.13)−0.00 (− 0.15, 0.15)−0.03 (− 0.16, 0.10)−0.04 (− 0.23, 0.15)Results are mean (95% confidence interval). Bold slope estimates = p < 0.05. All analyses were adjusted for study. The analyses on MMSE scores were also corrected for demographics and baseline diagnosisAbbreviations: Aβ amyloid-beta, MMSE mini mental state examination, WMH white matter HyperintensitiesAp < 0.05 compared to Aβ- WMH-Bp < 0.05 compared to Aβ- WMH+.Cp < 0.05 compared to Aβ + WMH-.Dp < 0.05 compared to Aβ + WMH+.   Source: http://doi.org/10.1186/s13195-018-0391-x

 

Leave a Reply

Your email address will not be published.